- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
December 31st, 2007
"My favorite speculation for 2008 is Australia-based Starpharma (OTC: SPHRY), a 'home run' pick," says Gregg Early in The Real Nanotech Investor.
"The drug delivery sector has been revolutionized by the application of nanotechnologies. And one of the fastest up-and-coming countries in this sector is Australia.
"Starpharma has landed a few significant co-development and assessment deals with some major firms in recent months as it awaits FDA approval for its VivaGel, dendrimer-based topical cream that can prevent the spread of sexually transmitted diseases, specifically Herpes and HIV.
"VivaGel also has spermicidal qualities that are so compelling, one of Starpharma's recent co-development deals was with Durex, one of the world's top condom manufacturers. Durex is considering replacing the near-ubiquitous Non-oxynol 9 spermicidal coating with VivaGel, which is proving to be safe and more effective than N-9.
|Related News Press|
News and information
Graphenea celebrates fifth anniversary April 27th, 2015
Harris & Harris Group Sponsors NYC American Heart Association's Health Sciences Innovation Investment Forum: Co-founder of Harris & Harris Group Portfolio Company TARA Biosystems to Speak About the Value of Tissue Engineering Technology April 21st, 2015
Long Island Capital Alliance Announces Participants for Brookhaven National Laboratory Technology Transfer Capital Forum on May 8: Keynote Speaker Dr. Doon Gibbs, Director of Brookhaven National Laboratory April 16th, 2015
Graphenea embarks on a new era April 16th, 2015
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers
Cacao Seed Extract Used in Production of Catalytic Nanoparticles April 27th, 2015
Heat makes electronsí spin in magnetic superconductors April 26th, 2015